menu

HER2+ Metastatic Breast Cancer Therapies: Managing Adverse Events

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

HER2+ Metastatic Breast Cancer Therapies: Managing Adverse Events

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    One adverse event that has highly impacted the treatment landscape for HER2+ metastatic breast cancer (mBC) patients is the risk of interstitial lung disease, or pneumonitis, related to the antibody-drug conjugates, particularly trastuzumab/deruxtecan. So how should we be monitoring for these adverse events? Find out as Dr. Pavani Chalasani speaks with Dr. Megan Kruse, Breast Medical Oncologist and Director of Breast Cancer Research at the Cleveland Clinic in Ohio. 

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    One adverse event that has highly impacted the treatment landscape for HER2+ metastatic breast cancer (mBC) patients is the risk of interstitial lung disease, or pneumonitis, related to the antibody-drug conjugates, particularly trastuzumab/deruxtecan. So how should we be monitoring for these adverse events? Find out as Dr. Pavani Chalasani speaks with Dr. Megan Kruse, Breast Medical Oncologist and Director of Breast Cancer Research at the Cleveland Clinic in Ohio. 

Facebook Comments

Schedule22 Jun 2024